David Tyas

Statistics

Publications

Citations

334

H-Index

Active since

2006

Affiliations

Augmentium Pharma Consulting (Canada)(Current)

Bristol-Myers Squibb (United Kingdom)

Bristol-Myers Squibb (United States)

Monash University

Health Economics and Outcomes Research (United Kingdom)

David Tyas is an author at Augmentium Pharma Consulting (Canada) specializing in cancer immunotherapy, metastatic melanoma treatment, and model-based economic evaluation.

Publications per year

2006–2019

Publications

The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UK

Michelle Orme, John Kerrigan, David Tyas et al. · Value in Health · 2006 · 168 citations · Full text

Medicine, Neurology, Functional Decline +10

Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation

Ian Koblbauer, Najida Begum, George Dranitsaris et al. · PharmacoEconomics · 2017 · 65 citations · Full text

Public Health, Biostatistics, Oncology +17

The Distribution of the Cost of Multiple Sclerosis in the UK: How Do Costs Vary by Illness Severity?

David Tyas, John Kerrigan, Nicola S. Russell et al. · Value in Health · 2007 · 34 citations · Full text

Pharmacy, Neurology, Pharmacoeconomics +16

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom

Korinna Karampampa, Anders Gustavsson, Carolin Miltenburger et al. · Multiple Sclerosis Journal · 2012 · 27 citations

Nursing, Psychiatry, Health Assessment +13

Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma

Edward Gibson, Najida Begum, Ian Koblbauer et al. · Journal of Medical Economics · 2019 · 25 citations · Full text

Pharmacy, Biostatistics, Oncology +17

1–5 of 6